Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 3Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5Terminated 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Neoplasms 282Carcinoma, Non-Small-Cell Lung 253Leukemia, Myeloid, Acute 190Breast Neoplasms 153Melanoma 151Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 114Lymphoma 113Leukemia, Lymphocytic, Chronic, B-Cell 108Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 86Prostatic Neoplasms 83Lung Neoplasms 82Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 68Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 51

Interventions

capmatinib 1Radiotherapy, Intensity-Modulated 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Laryngeal Diseases × Clear all
NCT06056310 2025-09-29

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

EMD Serono

Phase 1 Terminated
18 enrolled 9 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Diseases

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis

Phase 1 Terminated
13 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡